MoneyWorks4Me

Brooks Laboratories acquires 44.33% stake in SteriBrooks Penems

18 Sep 2020 Evaluate

Brooks Laboratories has subscribed to 7963 equity shares at the face value of Rs 10 each of SteriBrooks Penems, amounting to 44.33% of the post issue paid-up shares capital of SteriBrooks. The object of the said acquisition is to build a robust carbapenem business with integrated manufacturing capabilities.  

Brooks Laboratories has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials.

Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1237.65
Cipla 1313.80
Lupin 1957.00
Zydus Lifesciences 1117.30
View more..